EGFR and non-small cell lung carcinoma: We speculate that this observation may be explained by the recent finding of subclonal EGFR driver mutations in 3 of 21 (14%) NSCLC cases (McGranahan et al, 2015), and suggest that monitoring EGFR‐targeted therapies by ctDNA would require tracking mutations beyond EGFR.